Eton Pharmaceuticals to be Acquired by Luye Pharma Group
Ticker: ETON · Form: 8-K · Filed: Dec 17, 2024 · CIK: 1710340
Sentiment: bullish
Topics: acquisition, merger, pharmaceuticals
TL;DR
Eton Pharma going private for $1.10/share cash deal with Luye Pharma.
AI Summary
Eton Pharmaceuticals, Inc. announced on December 17, 2024, that it has entered into a definitive agreement to be acquired by a subsidiary of Luye Pharma Group Ltd. for $1.10 per share in cash. This transaction is expected to close in the first half of 2025, subject to customary closing conditions and regulatory approvals.
Why It Matters
This acquisition by a larger pharmaceutical company could lead to expanded market access and resources for Eton's products, potentially benefiting patients and shareholders.
Risk Assessment
Risk Level: medium — The acquisition is subject to closing conditions and regulatory approvals, which introduces uncertainty until completion.
Key Numbers
- $1.10 — Acquisition Price Per Share (Cash consideration offered to Eton shareholders.)
Key Players & Entities
- Eton Pharmaceuticals, Inc. (company) — Registrant
- Luye Pharma Group Ltd. (company) — Acquiring entity
- $1.10 (dollar_amount) — Per share acquisition price
- December 17, 2024 (date) — Date of report and agreement
- first half of 2025 (date) — Expected closing period
FAQ
What is the total value of the acquisition?
The filing does not explicitly state the total value of the acquisition, but it is based on a price of $1.10 per share.
Who is acquiring Eton Pharmaceuticals?
Eton Pharmaceuticals is being acquired by a subsidiary of Luye Pharma Group Ltd.
When is the acquisition expected to close?
The transaction is expected to close in the first half of 2025.
What is the form of consideration for the acquisition?
The acquisition will be made for $1.10 per share in cash.
Are there any conditions to closing the acquisition?
Yes, the transaction is subject to customary closing conditions and regulatory approvals.
Filing Stats: 482 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2024-12-17 07:05:13
Key Financial Figures
- $0.001 — h registered Common Stock , par value $0.001 per share ETON NASDAQ Global Market
Filing Documents
- eton20241216_8k.htm (8-K) — 26KB
- ex_758050.htm (EX-99.1) — 16KB
- 0001437749-24-037689.txt ( ) — 177KB
- eton-20241217.xsd (EX-101.SCH) — 3KB
- eton-20241217_def.xml (EX-101.DEF) — 11KB
- eton-20241217_lab.xml (EX-101.LAB) — 15KB
- eton-20241217_pre.xml (EX-101.PRE) — 11KB
- eton20241216_8k_htm.xml (XML) — 3KB
01: Other Events
Item 8.01: Other Events On December 17, 2024, Eton Pharmaceuticals, Inc. (the "Company") issued a press release announcing the full readout and compelling results from the clinical trial evaluating PKU GOLIKE as a protein substitute for the treatment of phenylketonuria (PKU) in patients during prolonged fasting periods. The study demonstrated that PKU GOLIKE, administered as the last daily dose and compared to standard amino acid protein substitutes, improved metabolic control by reducing harmful phenylalanine (Phe) levels and increasing beneficial tyrosine (Tyr) levels, both essential for brain function and metabolic health. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. 2
01: Financial Statements and Exhibits
Item 9.01: Financial Statements and Exhibits Exhibit No. Description Exhibit 99.1 Press Release dated December 17, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 3
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 17, 2024 By: /s/ James R. Gruber James R. Gruber Chief Financial Officer and Secretary (Principal Financial Officer) 4